im体育

服务(wu)热线

+8610-84928167

hIL-3 NPG 小鼠

1. 基本(ben)信息

品系名(ming)称  NOD. Prkdcscid Il2rgtm1 Vst Tg(Csf1p -IL3)Vst/Vst

常用名  hIL-3 NPG /Vst; hIL-3 NPG

背景  NOD-scid/NcrCrl

毛色(se)   白色(se)


品系建(jian)立:

采(cai)用转基因的(de)方法(fa),构(gou)建pCDNA3.1-Csf1p-IL3载体,将线性(xing)化(hua)Csf1p-IL3表(biao)达(da)(da)序列(lie)注射到(dao)NPG小鼠的(de)原核中,在获得的(de)后代中筛选到(dao)合适表(biao)达(da)(da)量的(de)阳性(xing)小鼠。

在隔离器(qi)中,按照近交的方式(shi)扩繁建立商品化的hIL-3 NPG小鼠品系。


2. 表型

在NPG小(xiao)(xiao)鼠中表(biao)(biao)达(da)人的hIL-3细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)因子。白细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)介(jie)素3刺激多(duo)能(neng)造(zao)血(xue)干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分(fen)化(hua)(hua)为髓系祖细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)。可以与表(biao)(biao)达(da)人GM-CSF、M-CSF细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)因子的NPG小(xiao)(xiao)鼠一起(qi),在移植人CD34+造(zao)血(xue)干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)6-8周后(hou),于(yu)外周血(xue)、骨(gu)髓、胸腺(xian)和脾(pi)脏以及包(bao)括肺和肝在内的非淋巴组织中,形成(cheng)稳定广(guang)泛的髓系和淋巴系细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分(fen)化(hua)(hua)。在血(xue)液和组织中,可检测到粒细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分(fen)化(hua)(hua)(嗜碱性(xing)(xing)粒细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)、中性(xing)(xing)粒细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)和肥大细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)),抗原呈递(di)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)分(fen)化(hua)(hua)(树突状细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)和巨噬细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao))和调(diao)节性(xing)(xing)T细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)群(qun)体等。表(biao)(biao)达(da)人M-CSF、GM-CSF和人IL-3细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)因子与Hu-NPG人源(yuan)化(hua)(hua)小(xiao)(xiao)鼠相比,人类造(zao)血(xue)干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(hsc)的整体植入水平更高,分(fen)化(hua)(hua)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)种(zhong)类更多(duo)。


3. 应用(yong)领(ling)域

-人源化和癌症治疗(liao)

-人体过敏反应模型,免疫、造血移植(zhi)重建模型

-再生(sheng)医(yi)学(xue)

-感染性疾病

-生物医学


4. 参考文献

(1)Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.

(2)Wunderlich M; Chou FS; Link KA; Mizukawa B; Perry RL; Carroll M; Mulloy JC. 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24(10):1785-8.

(3)Billerbeck E; Barry WT; Mu K; Dorner M; Rice CM; Ploss A. 2011. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R{gamma}null humanized mice. Blood 117(11):3076-86.

(4)Coughlan AM; Harmon C; Whelan S; O'Brien EC; O'Reilly VP; Crotty P; Kelly P; Ryan M; Hickey FB; O'Farrelly C; Little MA. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev 25(7):530-41.